Information Provided By:
Fly News Breaks for October 5, 2015
ATRC
Oct 5, 2015 | 07:26 EDT
Canaccord said they would be buyers of AtriCure on any weakness associated with its dilutive acquisition of cardiac device maker nContact. The firm noted investors reaction tends to be overblown when acquisitions are dilutive, however, they feel the purchase will strengthen and expedite the company's push into the standalone MIS AF ablation marketplace. Canaccord reiterated its Buy rating and $31 price target on AtriCure shares.
News For ATRC From the Last 2 Days
There are no results for your query ATRC